Company profile for iX Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

iX Biopharma Ltd is a Singapore public-listed late-stage specialty pharmaceutical company with a keen focus on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions. Our Company operates a fully integrated business model, with its fully-licensed facilities in Melbourne, Australia. Our Company is able to undertake drug development...
iX Biopharma Ltd is a Singapore public-listed late-stage specialty pharmaceutical company with a keen focus on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions. Our Company operates a fully integrated business model, with its fully-licensed facilities in Melbourne, Australia. Our Company is able to undertake drug development and formulation, laboratory testing, manufacturing and the supply of its products to consumers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Singapore
Address
Address
1 Kim Seng Promenade #14-01 Great World City East Tower
Telephone
Telephone
+65 6235 2270
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.expresspharma.in/emcure-launches-emcutix-biopharmaceuticals-to-expand-its-dermatology-offerings/

#N/A
28 Oct 2024

https://www.prnewswire.com/news-releases/new-study-demonstrates-that-sl-nad-delivers-nad-into-cells-302235588.html

PR NEWSWIRE
01 Sep 2024

https://www.prnewswire.com/news-releases/ix-biopharma-signs-exclusive-license-agreement-for-wafermine-and-other-sublingual-ketamine-wafer-products-301432286.html

PRNEWSWIRE
29 Nov 2021

https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-acquisition-of-an-exclusive-license-of-ix-biopharmas-proprietary-wafer-based-delivery-platform-for-sublingual-ketamine-301431260.html

PRNEWSWIRE
24 Nov 2021

https://www.prnewswire.com/news-releases/ix-biopharmas-xativatm-bags-cbd-product-of-the-year-accolade-from-the-australian-cannabis-industry-awards-2020-301187990.html

PRNEWSWIRE
08 Dec 2020

https://www.prnewswire.com/news-releases/ix-biopharma-receives-positive-ema-scientific-advice-for-waferminetm-301187988.html#:~:text=SINGAPORE%2C%20Dec.%208%2C%202020,its%20Phase%203%20clinical%20development

PRNEWSWIRE
08 Dec 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty